This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
by Kinjel Shah
GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.
Here's Why GSK (GSK) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
by Zacks Equity Research
GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for review by the EMA.
Is FrancoNevada (FNV) Stock Outpacing Its Basic Materials Peers This Year?
by Zacks Equity Research
Here is how Franco-Nevada (FNV) and Fortuna Mining (FSM) have performed compared to their sector so far this year.
Is Central Japan Railway Co. (CJPRY) Stock Outpacing Its Transportation Peers This Year?
by Zacks Equity Research
Here is how Central Japan Railway Co. (CJPRY) and Copa Holdings (CPA) have performed compared to their sector so far this year.
Is Adyen (ADYEY) Stock Outpacing Its Computer and Technology Peers This Year?
by Zacks Equity Research
Here is how Adyen N.V. Unsponsored ADR (ADYEY) and Intuit (INTU) have performed compared to their sector so far this year.
Is EPR Properties (EPR) Stock Outpacing Its Finance Peers This Year?
by Zacks Equity Research
Here is how EPR Properties (EPR) and Aviva (AVVIY) have performed compared to their sector so far this year.
Are Consumer Discretionary Stocks Lagging Accel Entertainment (ACEL) This Year?
by Zacks Equity Research
Here is how Accel Entertainment (ACEL) and Sendas Distribuidora S.A. Sponsored ADR (ASAIY) have performed compared to their sector so far this year.
Are Construction Stocks Lagging EMCOR Group (EME) This Year?
by Zacks Equity Research
Here is how Emcor Group (EME) and Alfa Laval AB Unsponsored ADR (ALFVY) have performed compared to their sector so far this year.
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amarin (AMRN) and GSK (GSK) have performed compared to their sector so far this year.
Is AppLovin (APP) Stock Outpacing Its Business Services Peers This Year?
by Zacks Equity Research
Here is how AppLovin (APP) and Alithya Group (ALYAF) have performed compared to their sector so far this year.
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
by Zacks Equity Research
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Here's Why GSK (GSK) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
by Zacks Equity Research
Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.
FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch
by Zacks Equity Research
GSK's NDA for linerixibat, for treating itch in PBC patients, gets FDA review with a decision due in March 2026.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
by Ekta Bagri
GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However, we recommend investors remain on the sidelines at current levels.
Pharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline Updates
by Kinjel Shah
LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine funding, while SNY sees mixed COPD data.
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal
by Zacks Equity Research
SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how GSK (GSK) and Amarin (AMRN) have performed compared to their sector so far this year.
Buy 5 High Dividend-Paying Giants to Stay Safe Amid Volatile Markets
by Nalak Das
PM, CVS, ET, GSK and NWG, which offer high dividends and carry Zacks buy ranks, are strong picks for stability amid volatile market conditions of 2025.